Avid Bioservices, Inc. reiterating revenue guidance for the fiscal year 2022. The company is reiterating revenue guidance for fiscal 2022 of $115 million to $117 million, a 20% to 22% increase over fiscal 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.28 USD | +8.52% | +3.89% | +27.38% |
Apr. 30 | RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating | MT |
Apr. 29 | Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.38% | 484M | |
-0.28% | 90.59B | |
0.00% | 38.99B | |
-8.52% | 34.09B | |
+64.13% | 26.38B | |
-17.37% | 15.02B | |
-5.99% | 13.17B | |
-10.69% | 11.88B | |
-47.78% | 10.65B | |
+8.09% | 9.25B |
- Stock Market
- Equities
- CDMO Stock
- News Avid Bioservices, Inc.
- Avid Bioservices, Inc. Reiterates Revenue Guidance for the Fiscal Year 2022